Literature DB >> 31408792

Study on the stereoselective binding of cytosine nucleoside enantiomers to human serum albumin.

Cai Liu1, Jingjing Guo1, Fengling Cui2.   

Abstract

Nucleoside drugs are known for their remarkable anticancer and antiviral properties. The development of nucleoside drugs has attracted much attention and generated a great deal of research interest. β-L-cytidine and β-D-cytidine are a pair of cytosine nucleoside enantiomers. In this work, the interactions between cytosine nucleoside enantiomers and human serum albumin were studied by ultraviolet-visible spectra, fluorescence spectrum and circular dichroism spectrum under simulated human physiological environment. The data of fluorescence spectra were corrected for the inner-filter effect to improve accuracy. Stern-Volmer quenching constants and binding constants in addition to thermodynamic parameters have been analyzed, which established that complexes formation have taken place via static quenching mechanism, and that hydrophobic force involved in these interactions. CD spectrum revealed that on addition of cytosine nucleoside enantiomers, the α-helix% of HSA increased slightly. What's more, molecular modeling method indicated that cytosine nucleoside enantiomers prefer binding at the IIIA site of HSA.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Binding mechanism; Cytosine nucleoside enantiomers; Human serum albumin; Molecular modeling; Multispectral technique; Stereoselective

Mesh:

Substances:

Year:  2019        PMID: 31408792     DOI: 10.1016/j.saa.2019.117452

Source DB:  PubMed          Journal:  Spectrochim Acta A Mol Biomol Spectrosc        ISSN: 1386-1425            Impact factor:   4.098


  1 in total

1.  Testing for Ketoprofen Binding to HSA Coated Magnetic Nanoparticles under Normal Conditions and after Oxidative Stress.

Authors:  Marta Ziegler-Borowska; Kinga Mylkie; Pawel Nowak; Patryk Rybczynski; Adam Sikora; Dorota Chelminiak-Dudkiewicz; Anna Kaczmarek-Kedziera
Journal:  Molecules       Date:  2020-04-22       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.